NASDAQ:ONTX

Onconova Therapeutics Stock Forecast, Price & News

$7.07
-0.08 (-1.12 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.97
$7.24
50-Day Range
$0.73
$16.20
52-Week Range
$2.85
$28.95
Volume590,945 shs
Average Volume2.66 million shs
Market Capitalization$111.57 million
P/E RatioN/A
Dividend YieldN/A
Beta1.61
30 days | 90 days | 365 days | Advanced Chart
Receive ONTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Onconova Therapeutics logo

About Onconova Therapeutics

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.18 out of 5 stars

Medical Sector

989th out of 2,096 stocks

Pharmaceutical Preparations Industry

487th out of 830 stocks

Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions

Is Onconova Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Onconova Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONTX, but not buy additional shares or sell existing shares.
View analyst ratings for Onconova Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Onconova Therapeutics?

Wall Street analysts have given Onconova Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Onconova Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Onconova Therapeutics?

Onconova Therapeutics saw a decline in short interest in May. As of May 28th, there was short interest totaling 719,900 shares, a decline of 82.4% from the May 13th total of 4,080,000 shares. Based on an average daily volume of 1,410,000 shares, the days-to-cover ratio is presently 0.5 days. Currently, 4.9% of the company's stock are short sold.
View Onconova Therapeutics' Short Interest
.

When is Onconova Therapeutics' next earnings date?

Onconova Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Onconova Therapeutics
.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics, Inc. (NASDAQ:ONTX) issued its quarterly earnings results on Monday, May, 17th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.15. The biopharmaceutical company earned $0.06 million during the quarter, compared to analysts' expectations of $0.06 million. Onconova Therapeutics had a negative net margin of 10,544.68% and a negative trailing twelve-month return on equity of 139.26%.
View Onconova Therapeutics' earnings history
.

How has Onconova Therapeutics' stock price been impacted by Coronavirus?

Onconova Therapeutics' stock was trading at $5.40 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ONTX shares have increased by 30.9% and is now trading at $7.07.
View which stocks have been most impacted by COVID-19
.

When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?

Onconova Therapeutics shares reverse split before market open on Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 20th 2021. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for ONTX?

5 brokers have issued 1-year price objectives for Onconova Therapeutics' shares. Their forecasts range from $4.00 to $30.00. On average, they expect Onconova Therapeutics' share price to reach $18.06 in the next twelve months. This suggests a possible upside of 155.5% from the stock's current price.
View analysts' price targets for Onconova Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Onconova Therapeutics' key executives?

Onconova Therapeutics' management team includes the following people:
  • Dr. Steven M. Fruchtman, CEO, Pres & Director (Age 70, Pay $865.44k)
  • Mr. Mark Patrick Guerin, Chief Financial Officer (Age 52, Pay $512.19k)
  • Mr. Abraham N. Oler J.D., M.B.A., Esq., CFA, Sr. VP of Corp. Devel. & Gen. Counsel (Age 45)
  • Dr. Ramesh Kumar, Advisor (Age 65)

Who are some of Onconova Therapeutics' key competitors?

What other stocks do shareholders of Onconova Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM).

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

Who are Onconova Therapeutics' major shareholders?

Onconova Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.89%), Renaissance Technologies LLC (1.56%), Millennium Management LLC (1.19%), Geode Capital Management LLC (0.87%), Principal Financial Group Inc. (0.53%) and Principal Financial Group Inc. (7.97%). Company insiders that own Onconova Therapeutics stock include 683 Capital Management, Llc, Abraham N Oler, E Premkumar Reddy, James J Marino, Jerome Groopman, Mark Patrick Guerin, Steven M Fruchtman and Tyndall Capital Partners L P.
View institutional ownership trends for Onconova Therapeutics
.

Which institutional investors are selling Onconova Therapeutics stock?

ONTX stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Citadel Advisors LLC, Beacon Pointe Advisors LLC, and MONECO Advisors LLC.
View insider buying and selling activity for Onconova Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Onconova Therapeutics stock?

ONTX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlackRock Inc., Millennium Management LLC, Ikarian Capital LLC, Geode Capital Management LLC, Alyeska Investment Group L.P., HRT Financial LP, and Squarepoint Ops LLC. Company insiders that have bought Onconova Therapeutics stock in the last two years include Abraham N Oler, E Premkumar Reddy, James J Marino, Jerome Groopman, Mark Patrick Guerin, and Steven M Fruchtman.
View insider buying and selling activity for Onconova Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Onconova Therapeutics?

Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Onconova Therapeutics' stock price today?

One share of ONTX stock can currently be purchased for approximately $7.07.

How much money does Onconova Therapeutics make?

Onconova Therapeutics has a market capitalization of $111.57 million and generates $230,000.00 in revenue each year. The biopharmaceutical company earns $-25,160,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis.

How many employees does Onconova Therapeutics have?

Onconova Therapeutics employs 11 workers across the globe.

What is Onconova Therapeutics' official website?

The official website for Onconova Therapeutics is www.onconova.com.

Where are Onconova Therapeutics' headquarters?

Onconova Therapeutics is headquartered at 375 PHEASANT RUN, NEWTOWN PA, 18940.

How can I contact Onconova Therapeutics?

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected]


This page was last updated on 6/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.